PriceTargets.com logo

Chiasma - CHMA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.76 As of 09/15/2021 01:00 AM ET
+0 (0.00%)
Get New Chiasma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHMA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Chiasma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.76.

This chart shows the closing price for CHMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Chiasma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
5/5/2021Piper SandlerDowngradeOverweight ➝ Neutral
3/2/2021HC WainwrightBoost TargetBuy$10.00 ➝ $12.00
1/11/2021Piper SandlerLower Target$19.00 ➝ $15.00
1/8/2021HC WainwrightReiterated RatingBuy$10.00
8/13/2020Jefferies Financial GroupInitiated CoverageBuy$8.00
8/12/2020HC WainwrightLower TargetBuy$11.00 ➝ $10.00
7/7/2020Piper SandlerLower Target$22.00 ➝ $19.00
6/29/2020HC WainwrightBoost TargetBuy$10.00 ➝ $11.00
4/9/2020HC WainwrightReiterated RatingBuy$10.00
3/17/2020Cantor FitzgeraldReiterated RatingOverweight
3/17/2020HC WainwrightLower TargetBuy$11.00 ➝ $10.00
1/14/2020Piper SandlerBoost TargetOverweight$11.00 ➝ $13.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Chiasma logo
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Read More

Today's Range

Now: $3.76
Low: $3.76
High: $3.76

50 Day Range

MA: $4.01
Low: $3.76
High: $4.71

52 Week Range

Now: $3.76
Low: $2.77
High: $5.74

Volume

147 shs

Average Volume

2,123,740 shs

Market Capitalization

$217.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Chiasma?

The following Wall Street sell-side analysts have issued reports on Chiasma in the last year: StockNews.com.
View the latest analyst ratings for CHMA.

What is the current price target for Chiasma?

0 Wall Street analysts have set twelve-month price targets for Chiasma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Chiasma in the next year.
View the latest price targets for CHMA.

What is the current consensus analyst rating for Chiasma?

Chiasma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CHMA.

What other companies compete with Chiasma?

Other companies that are similar to Chiasma include Strongbridge Biopharma, OptiNose, Xeris Biopharma, Nuvation Bio and Capricor Therapeutics. Learn More about companies similar to Chiasma.

How do I contact Chiasma's investor relations team?

Chiasma's physical mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company's listed phone number is 617-928-5300 and its investor relations email address is [email protected]. The official website for Chiasma is www.chiasmapharma.com. Learn More about contacing Chiasma investor relations.